This study documents the screening performance, in practice, of a publ
ished protocol for interpreting second-trimester Down syndrome risk in
twin pregnancies, using maternal serum biochemical markers. Within a
cohort of 35 150 pregnancies, 410 twin pregnancies were identified. Th
e rate of twinning was positively associated with maternal age. Of the
274 twin pregnancies known prior to screening, 15 (5.5 per cent) were
classified as being screen-positive for Down syndrome. When maternal
age and dating method were taken into account, the screen-positive rat
es in twin and singleton pregnancies did not differ significantly. Nin
e of the 14 screen-positive women with viable twin pregnancies chose a
mniocentesis [64 per cent, 95 per cent confidence interval (CI) 35-87]
. No cases of Down syndrome were identified. Based on modelling, an es
timated 73 per cent of monozygotic twin pregnancies and 43 per cent of
dizygotic twin pregnancies with Down syndrome would be identified at
a 5 per cent false-positive rate. The overall detection rate would be
about 53 per cent. When laboratories offer multiple marker screening t
o women with twin pregnancies, the false-positive rate ought to be sim
ilar to that found in singleton pregnancies; the detection rate is, ho
wever, likely to be lower for dizygotic twins.